Program
orelabrutinib
Also written as “ICP-022”, “Orelabrutinib” and “ICP-248+Orelabrutinib”.
Its studies are mostly in Lymphoma, Mantle-Cell · Lupus Erythematosus, Systemic · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.
Drug pageOrelabrutinib: every studyAll 95 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InnoCare Pharmaits history only | 2511 open or running | phase 3since Oct 1, 2020 | Jun 12, 2017 | Aug 31, 2028phase 3 · NCT06082102 |
| Zenas BioPharma (USA) | 22 open or running | phase 3since Jul 3, 2025 | Jul 3, 2025 | Jun 2030phase 3 · NCT07299019 |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseZenas BioPharma licensed it from InnoCare, for multiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia.Announced Oct 8, 2025 · Source: Zenas BioPharma and InnoCare (release), Oct 8, 2025
History and studies of Zenas BioPharma (USA) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named orelabrutinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ICP-022
- Jul 3, 2025First study: phase 3 study in Multiple Sclerosis, Chronic ProgressiveFirst studyNCT07067463 · 705 planned · United States, Australia, Bulgaria and more
- Oct 8, 2025Zenas BioPharma licensed it from InnoCareLicenseMultiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia · announced · Zenas BioPharma and InnoCare (release)
- Dec 18, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07299019 · 990 planned · United States, Australia, Belgium and more
Ahead
- Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07299019
- Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07067463
TargetBeta
“A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 2 Zenas BioPharma (USA) leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07299019Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more | 3 | Recruiting | Jun 2030 | 990 |
| NCT07067463Multiple Sclerosis, Chronic Progressive · United States, Australia, Bulgaria and more | 3 | Recruiting | Jun 2030 | 705 |
How it is read
Names in the registry
- “ICP-022”, 11 entries
- “Orelabrutinib”, 7 entries
- “ICP-248+Orelabrutinib”, 3 entries
- “Orelabrutinib High dose”, 1 entry
- “Orelabrutinib Low dose”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 4 studies
- Lupus Erythematosus, Systemic, 3 studies
- Multiple Sclerosis, Chronic Progressive, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.